Document Detail


Hypertrophic cardiomyopathy.
MedLine Citation:
PMID:  22874472     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Hypertrophic cardiomyopathy is a common inherited cardiovascular disease present in one in 500 of the general population. It is caused by more than 1400 mutations in 11 or more genes encoding proteins of the cardiac sarcomere. Although hypertrophic cardiomyopathy is the most frequent cause of sudden death in young people (including trained athletes), and can lead to functional disability from heart failure and stroke, the majority of affected individuals probably remain undiagnosed and many do not experience greatly reduced life expectancy or substantial symptoms. Clinical diagnosis is based on otherwise unexplained left-ventricular hypertrophy identified by echocardiography or cardiovascular MRI. While presenting with a heterogeneous clinical profile and complex pathophysiology, effective treatment strategies are available, including implantable defibrillators to prevent sudden death, drugs and surgical myectomy (or, alternatively, alcohol septal ablation) for relief of outflow obstruction and symptoms of heart failure, and pharmacological strategies (and possibly radiofrequency ablation) to control atrial fibrillation and prevent embolic stroke. A subgroup of patients with genetic mutations but without left-ventricular hypertrophy has emerged, with unresolved natural history. Now, after more than 50 years, hypertrophic cardiomyopathy has been transformed from a rare and largely untreatable disorder to a common genetic disease with management strategies that permit realistic aspirations for restored quality of life and advanced longevity.
Authors:
Barry J Maron; Martin S Maron
Publication Detail:
Type:  Journal Article; Review     Date:  2012-08-06
Journal Detail:
Title:  Lancet     Volume:  381     ISSN:  1474-547X     ISO Abbreviation:  Lancet     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-01-21     Completed Date:  2013-02-07     Revised Date:  2013-04-29    
Medline Journal Info:
Nlm Unique ID:  2985213R     Medline TA:  Lancet     Country:  England    
Other Details:
Languages:  eng     Pagination:  242-55     Citation Subset:  AIM; IM    
Copyright Information:
Copyright © 2013 Elsevier Ltd. All rights reserved.
Affiliation:
The Hypertrophic Cardiomyopathy Centers of Minneapolis Heart Institute Foundation, Minneapolis, MN, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Cardiomyopathy, Hypertrophic* / complications,  diagnosis,  genetics,  therapy
Death, Sudden, Cardiac / etiology,  prevention & control
Humans
Comments/Corrections
Comment In:
Lancet. 2013 Apr 27;381(9876):1456-7   [PMID:  23622276 ]
Lancet. 2013 Apr 27;381(9876):1457-8   [PMID:  23622278 ]
Lancet. 2013 Apr 27;381(9876):1456   [PMID:  23622277 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Acid-base status and progression of chronic kidney disease.
Next Document:  Single Stage Anterior Release and Sequential Posterior Fusion for Irreducible Atlantoaxial Dislocati...